stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) P/B ratio
As of 6 November 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a P/B ratio of 1.7×. Over the past ten years it has ranged from 1.5× (May 2026) to 12.4× (March 2015); the current reading is higher than 4% of that period. That is below the Biotechnology industry median of 2.0× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.9× | (15.18%) |
| FY2024 | 2.2× | (40.65%) |
| FY2023 | 3.7× | (8.14%) |
| FY2022 | 4.0× | 6.92% |
| FY2021 | 3.8× | (1.92%) |
| FY2020 | 3.9× | (20.35%) |
| FY2019 | 4.8× | (4.56%) |
| FY2018 | 5.1× | (10.14%) |
| FY2017 | 5.7× | 9.76% |
| FY2016 | 5.2× | (26.24%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 1.9× | 6.05% |
| Jun 2026 | 1.8× | 0.01% |
| Mar 2026 | 1.8× | (6.52%) |
| Dec 2025 | 1.9× | 9.04% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| IBRX ImmunityBio, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. | 1.7× |
| PCVX Vaxcyte, Inc. compare | 3.3× |
| TECH Bio-Techne Corp compare | 5.4× |
| KYMR Kymera Therapeutics, Inc. compare | 7.8× |
| CAI Caris Life Sciences,�Inc. compare | 12.7× |
| TGTX TG Therapeutics, Inc. compare | 13.6× |
| TWST Twist Bioscience Corporation compare | 17.1× |
| SMMT Summit Therapeutics PLC compare | 17.8× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement